Exome sequencing

Caris Life Sciences to Showcase Research at 2024 SGO Annual Meeting on Women's Cancer

Retrieved on: 
Wednesday, March 13, 2024
Diagnosis, PR, UCS, NCI, Ovarian cancer, Promise, OSCC, Survival, EEC, Exome sequencing, Glomus tumor, TMB, Patient, Neoplasm, NGS, Biomarker, Research, DNA, RNA, Cancer, AI, SGO, Carcinosarcoma, MD, Endometrial cancer, Medicine, Abstract, POA, Prognosis, Poster, ETS, Medical imaging

IRVING, Texas, March 13, 2024 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI, announced today that the company and collaborators within the Caris Precision Oncology Alliance™ (POA) will collectively present three studies across multiple gynecological tumor types at the 2024 SGO Annual Meeting on Women's Cancer, March 16-18, 2024, in San Diego. The findings demonstrate the power of Caris' comprehensive multi-modal database, generated by examining every gene, to enable novel insights into cancer that could have profound effects on a patient's diagnosis, prognosis, care plan and response to treatment.

Key Points: 
  • The findings demonstrate the power of Caris' comprehensive multi-modal database, generated by examining every gene
    "We are proud to return and present an array of precision oncology research at this year's SGO Annual Meeting.
  • The Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) criteria classify four molecular subtypes of endometrial tumors (ET).
  • Poster and abstract summaries highlighting the Caris research presented at SGO 2024 will be available onsite at Caris' booth (#601).
  • The POA includes 91 cancer centers, academic institutions, research consortia and healthcare systems, including 43 NCI-designated cancer centers, collaborating to advance precision oncology and biomarker-driven research.

Genetic Health Service Provider, Panacea, Launches to Make Whole Exome Sequencing Accessible to Consumers Without Insurance Barriers

Retrieved on: 
Wednesday, February 28, 2024
PALM, Breast cancer, Dahlia, Sequence, BRCA, Risk, Health, Ovarian cancer, CLIA, Ashkenazi Jews, Exome sequencing, Disease, Science, Mutation, CAP, Insurance, Cancer, Vaccine

PALM BEACH, Fla., Feb. 28, 2024 /PRNewswire/ -- Panacea, the one-stop-shop for genetic health services making potentially life-saving testing accessible for consumers, today announced its nationwide* commercial availability, without needing to visit a doctor or receive approval from insurance.

Key Points: 
  • The problem is that current guidelines for doctors to order genetic tests, and for insurance to approve it, are missing about half of the people with genetic mutations.
  • "I had my exome sequenced with Panacea, even though I was not a candidate for testing based on today's medical guidelines.
  • This further inspired me to make clinical-grade whole exome sequencing more accessible, so everyone can make informed decisions about their future."
  • For more information on Panacea or on whole exome sequencing, please visit seekpanacea.com .

Whole Genome Sequencing Market Global Industry Forecast Report 2018-2028, Featuring Profiles of Illumina, Agilent Technologies, 10 x Genomics, BGI, Oxford Nanopore, Nebula Genomics & Veritas Genetics

Retrieved on: 
Wednesday, January 31, 2024
Cloud, Volcanic explosivity index, Whole genome sequencing, Growth, Microbiology, Workflow, WES, Genomics, Research, AI, DNA, Bacteria, Government, Gene, Mutation, Diagnosis, Microorganism, Exon, Competition, Exome sequencing, Sequence, Next Generation, NGS, Cloud computing, Cancer, Genome, Infection, Antibiotics

DUBLIN, Jan. 31, 2024 /PRNewswire/ -- The "Whole Genome Sequencing Market - Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, 2018-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Jan. 31, 2024 /PRNewswire/ -- The "Whole Genome Sequencing Market - Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, 2018-2028" report has been added to ResearchAndMarkets.com's offering.
  • The Whole Genome Sequencing Market is expected to grow with an impressive CAGR in the forecast period 2024-2028.
  • Increasing technological advancement in NGS instruments and update in technology utilized in Sequencing techniques are adding to further drive the sequencing market growth in the forecast period.
  • In this report, Whole Genome Sequencing Market has been segmented into the following categories:

BGI Australia Receives NATA Certification for Clinical Whole Exome Sequencing

Retrieved on: 
Thursday, October 20, 2022
Exome sequencing, Communication, Records manager, Medicine, Accreditation, Government, Achievement, Science, Technology transfer, Laboratory, National Association of Testing Authorities, QIMR Berghofer Medical Research Institute, Patient, Hospital, Sequence, Exome, Research, National Association, Technology, Certification, TGA, Quality management, Therapeutic Goods Administration, Industry, NATA, Health, MGI, BGI Group, CEO, Intellectual property, Pathology, Compliance, Medical device

BRISBANE, Australia, Oct. 20, 2022 /PRNewswire/ -- BGI Australia's lab has achieved accreditation from the National Association of Testing Authorities (NATA) to perform clinical Whole Exome Sequencingin Australia, paving the way for the global life sciences company to provide clinical sequencing services for identifyingpossible disease-causing genetic changes.

Key Points: 
  • BRISBANE, Australia, Oct. 20, 2022 /PRNewswire/ -- BGI Australia's lab has achieved accreditation from the National Association of Testing Authorities (NATA) to perform clinical Whole Exome Sequencingin Australia, paving the way for the global life sciences company to provide clinical sequencing services for identifyingpossible disease-causing genetic changes.
  • "We will continue to improve and increase the accessibility of clinical sequencing to clinical laboratories, research institutes and hospitals."
  • "The BGI Australia local staff are some of the highest quality I have worked with," said Dr Peter Kaub, a genetic pathologist and medical consultant to BGI Australia for clinical Whole Exome Sequencing.
  • "Receiving accreditation means that they can now service clinical Whole Exome Sequencing for any laboratories or hospitals that require it.

BGI Australia Receives NATA Certification for Clinical Whole Exome Sequencing

Retrieved on: 
Thursday, October 20, 2022
Exome sequencing, Communication, Records manager, Medicine, Accreditation, Government, Achievement, Science, Technology transfer, Laboratory, National Association of Testing Authorities, QIMR Berghofer Medical Research Institute, Patient, Hospital, Sequence, Exome, Research, National Association, Technology, Certification, TGA, Quality management, Therapeutic Goods Administration, Industry, NATA, Health, MGI, BGI Group, CEO, Intellectual property, Pathology, Compliance, Medical device

BRISBANE, Australia, Oct. 20, 2022 /PRNewswire/ -- BGI Australia's lab has achieved accreditation from the National Association of Testing Authorities (NATA) to perform clinical Whole Exome Sequencingin Australia, paving the way for the global life sciences company to provide clinical sequencing services for identifyingpossible disease-causing genetic changes.

Key Points: 
  • BRISBANE, Australia, Oct. 20, 2022 /PRNewswire/ -- BGI Australia's lab has achieved accreditation from the National Association of Testing Authorities (NATA) to perform clinical Whole Exome Sequencingin Australia, paving the way for the global life sciences company to provide clinical sequencing services for identifyingpossible disease-causing genetic changes.
  • "We will continue to improve and increase the accessibility of clinical sequencing to clinical laboratories, research institutes and hospitals."
  • "The BGI Australia local staff are some of the highest quality I have worked with," said Dr Peter Kaub, a genetic pathologist and medical consultant to BGI Australia for clinical Whole Exome Sequencing.
  • "Receiving accreditation means that they can now service clinical Whole Exome Sequencing for any laboratories or hospitals that require it.

Baylor Genetics and SRL, Inc. Initiate Clinical Grade of Whole Exome and Genome Sequencing Technology Transfer

Retrieved on: 
Wednesday, December 29, 2021
National, Spotless Group Holdings, Baylor University, R&D, WES, Technology transfer, LLC, Medical research, BG, No, GLOBE, Texas Medical Center, Genetic testing, Partnership, CEO, NIH, CMO, R, Precision medicine, LTS, Patient, Whole genome sequencing, WGS, Japan Agency for Medical Research and Development, Exome sequencing, Technology, SRL, Genetics, D, Baylor College of Medicine, Pharmaceutical industry

"I am confident that this collaboration enables SRL to provide optimal clinical sequencing for Japanese patients by applying the world's best technology with Baylor Genetics," said Kazuya Omi, R&D Executive Officer at SRL.

Key Points: 
  • "I am confident that this collaboration enables SRL to provide optimal clinical sequencing for Japanese patients by applying the world's best technology with Baylor Genetics," said Kazuya Omi, R&D Executive Officer at SRL.
  • As part of the agreement, BG will transfer its knowledge of WES and WGS as clinical services to SRL with technical support to enhance the Japanese lab's capabilities.
  • The technology transfer is expected to start in 2022 with efforts to contribute towards precision medicine application in Japan.
  • To learn more about Baylor Genetics' Whole Exome Sequencing services, visit: https://www.baylorgenetics.com/whole-exome-sequencing/
    To learn more about Baylor Genetics' Whole Genome Sequencing services, visit: https://www.baylorgenetics.com/whole-genome-sequencing/

Twist Bioscience Acquires NGS Library Preparation Maker iGenomX

Retrieved on: 
Wednesday, June 30, 2021
Science, Biotechnology, Nanotechnology, Research, Health, Technology, Genetics, Semiconductor, Branches of biology, Biology, Molecular biology, Life sciences, DNA sequencing, Biotechnology, DNA, In science, Twist Bioscience, Massive parallel sequencing, Duplex sequencing, Exome sequencing

Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the acquisition of iGenomX , a company offering multiplex library preparation tools for next-generation sequencing (NGS) workflows.

Key Points: 
  • Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the acquisition of iGenomX , a company offering multiplex library preparation tools for next-generation sequencing (NGS) workflows.
  • The iGenomX team built a robust PCR-like workflow for ultra-high throughput library construction that will further enable customers to convert from SNP microarray to an NGS-based approach, said Emily M. Leproust, Ph.D., CEO and co-founder of Twist.
  • iGenomX was founded in 2012 to develop and commercialize a high-throughput rapid library preparation that facilitates large sample volume with a simple workflow at enabling price points.
  • Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development.

Pacific Biosciences and Rady Children’s Institute for Genomic Medicine Announce its First Research Collaboration for Whole Genome Sequencing

Retrieved on: 
Wednesday, June 23, 2021
Branches of biology, Biology, Life sciences, Molecular biology, Biotechnology, DNA sequencing, Bioinformatics, Genomics, Pacific Biosciences, Exome sequencing, Whole genome sequencing, Third-generation sequencing

The study is focused on long-read whole genome sequencing of rare disease cases for which previous short-read whole genome and exome sequencing yielded no answers.

Key Points: 
  • The study is focused on long-read whole genome sequencing of rare disease cases for which previous short-read whole genome and exome sequencing yielded no answers.
  • We are very pleased by the preliminary results delivered in this collaboration with the team at PacBio.
  • Pacific Biosciences of California, Inc. (NASDAQ: PACB) is empowering life scientists with highly accurate long-read sequencing.
  • RCIGM is a non-profit, research institute of Rady Childrens Hospital and Health Center.

Veritas Intercontinental: Genetics makes it possible to identify cardiovascular genetic risk and prevent cardiac accidents such as those that have been in the news in recent days

Retrieved on: 
Tuesday, June 22, 2021
Branches of biology, Biology, Human genetics, Genetics, DNA sequencing, Exome sequencing, Molecular biology, Exome, Medical genetics, Disease, Genetic heterogeneity, Genotype-first approach

This type of incidence and the possible fatal consequences result from an individual's genetic makeup.

Key Points: 
  • This type of incidence and the possible fatal consequences result from an individual's genetic makeup.
  • The analysis includes all genes recommended by the American Heart Association (AHA) analyzing 100 genes based on their relationship with different hereditary heart diseases.
  • myCardio allows a comprehensive approach to heart disease, with a new perspective that has been shown to be much more effective".
  • Whole exome sequencing (WES) is the most appropriate tool to address the genetic heterogeneity present in inherited cardiovascular disease.

Veritas Intercontinental: Genetics makes it possible to identify cardiovascular genetic risk and prevent cardiac accidents such as those that have been in the news in recent days

Retrieved on: 
Tuesday, June 22, 2021
Branches of biology, Biology, Medical genetics, Applied genetics, Medical tests, Genetics, Human genetics, Genetic testing, Exome sequencing, Genetic counseling, Exome, Pathology

- Genetic diagnosis allows the patient to be referred to a specialist of the cardiological pathology detected, allowing appropriate management of the patient and genetic counseling for family members.

Key Points: 
  • - Genetic diagnosis allows the patient to be referred to a specialist of the cardiological pathology detected, allowing appropriate management of the patient and genetic counseling for family members.
  • MADRID, June 22, 2021 /PRNewswire/ -- We have recently witnessed, once again, a professional athlete suffering a cardiovascular attack during a match.
  • This type of incidence and the possible fatal consequences result from an individual's genetic makeup.
  • Whole exome sequencing (WES) is the most appropriate tool to address the genetic heterogeneity present in inherited cardiovascular disease.